РОЛЬ ФАКТОРА РОСТА ФИБРОБЛАСТОВ 23-го ТИПА В РАЗВИТИИ КАРДИОВАСКУЛЯРНЫХ ОСЛОЖНЕНИЙ И НАРУШЕНИЙ КАЛЬЦИЙ-ФОСФОРНОГО ОБМЕНА У ПАЦИЕНТОВ С ХРОНИЧЕСКОЙ БОЛЕЗНЬЮ ПОЧЕК
https://doi.org/10.24884/1607-4181-2015-22-1-38-42
Аннотация
Об авторах
А. М. ЕсаянРоссия
А. Н. Нимгирова
Россия
И. Г. Каюков
Россия
А. А. Яковенко
Россия
Список литературы
1. Смирнов А. В., Каюков И. Г., Добронравов В. А. Концепция факторов риска в нефрологии: вопросы профилактики и лечения хронической болезни почек // Нефрология. - 2008. - № 12 (1). - С. 7-13.
2. Bacchetta J., Dubourg L., Harambat J. et al. The influence of glomerular filtration rate and age on fibroblast growth factor 23 serum levels in pediatric chronic kidney disease // J. Clin. Endocrinol. Metab. - 2010. - № 95. - Р. 1741-1748.
3. Bhan I., Shah A., Holmes J. et al. Post-transplant hypophosphatemia: Tertiary Hyper-Phosphatoninism? // Kidney Int. - 2006. - № 70. - Р. 1486-1494.
4. Cai Q., Hodgson S. F., Kao P. C. et al. Brief report: inhibition of renal phosphate transport by a tumor product in a patient with oncogenic osteomalacia // N. Engl. J. Med. - 1994. -№ 330. - Р. 1645-1649.
5. Evenepoel P., Meijers B. K., de Jonge H. et al. Recovery of hyperphosphatoninism and renal phosphorus wasting one year after successful renal transplantation // Clin. J. Am. Soc. Nephrol. - 2008. - № 3. - Р. 1829-1836.
6. Evenepoel P., Naesens M., Claes K. et al. Tertiary ‘hyper-phosphatoninism' accentuates hypophosphatemia and suppresses calcitriol levels in renal transplant recipients // Am. J. Transplant. - 2007. - № 7. - Р. 1193-1200.
7. Fliser D., Kollerits B., Neyer U. et al. Fibroblast Growth Factor 23 (FGF23) predicts progression of chronic kidney disease: the mild to moderate kidney disease (MMKD) study // J. of the Am. Society of Nephrology. - 2007. - № 18 (9). -Р. 2600-2608.
8. Gattineni J., Bates C., Twombley K. et al. FGF23 decreases renal NaPi-2a and NaPi-2c expression and induces hypophosphatemia in vivo predominantly via FGF receptor 1 // Am. J. of Physiology: Renal Physiology. - 2009. - № 297 (2). -Р. 282-291.
9. Green J., Debby H., Lederer E. et al. Evidence for a PTH-independent humoral mechanism in post-transplant hypophosphatemia and phosphaturia // Kidney Int. - 2001. -№ 60. - Р. 1182-1196.
10. Gutierrez O. M., Mannstadt M., Isakova T. et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis // The New England J. of Medicine. - 2008. -№ 359 (6). - Р. 584-592.
11. Gutierrez O., Isakova T., Rhee E. et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease // J. Am. Soc. Nephrol. - 2005. - № 16. - Р. 2205 - 2215
12. Hansen D., Rasmussen K., Pedersen S. M. et al. Changes in fibroblast growth factor 23 during treatment of secondary hyperparathyroidism with alfacalcidol or paricalcitol // Nephrology Dialysis Transplantation. - 2012. - № 27 (6). - Р. 2263 - 2269.
13. Howard R. J., Patton P. R., Reed A. I. et al. The changing causes of graft loss and death after kidney transplantation // Transplantation - 2002. - № 73. - Р. 1923-1928.
14. Hsu H. J., Wu M. S. Fibroblast growth factor 23: a possible cause of left ventricular hypertrophy in hemodialysis patients // Am. J. Med. Sci. - 2009. - № 337. - Р. 116-122.
15. Isakova T., Xie H., Yang W. et al. Fibroblast Growth Factor 23 and Risks of Mortality and End-Stage Renal Disease in Patients with Chronic Kidney Disease // JAMA. - 2011. - № 305 (23). - Р. 2432 - 2439.
16. Jean G., Bresson E., Terrat J. C. et al. Peripheral vascular calcification in long-haemodialysis patients: associated factors and survival consequences // Nephrology Dialysis Transplantation. - 2009. - № 24 (3). - Р. 948 - 955.
17. Jean G., Terrat J. C., Vanel T. et al. High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients // Nephrology Dialysis Transplantation. - 2009. - № 24 (9). - Р. 2792 - 2796.
18. Katoh Y., Katoh M. Comparative genomics on mammalian FGF6-FGF23 locus // Int. J. of Molecular Medicine. - 2005. - № 16 (2). - Р. 355 - 358.
19. Kurosu H., Ogawa Y., Miyoshi. M. et al. Regulation of fibroblast growth factor-23 signaling by Klotho // J. Biol. Chem. - 2006. - № 281. - Р. 6120 - 6123.
20. Levi M. Post-transplant hypophosphatemia // Kidney Int. - 2001. - № 59. - Р. 2377 - 2387.
21. Middleton R. J., Parfrey P. S., Foley R. N. Left ventricular hypertrophy in the renal patient // J. Am. Soc. Nephrol. - 2001. - № 12. - Р. 1079- 1084.
22. Mirza M. A. I., Hansen T., Johansson L. et al. Relationship between circulating FGF23 and total body atherosclerosis in the community // Nephrology Dialysis Transplantation. - 2009. - № 24 (10). - Р. 3125 - 3131.
23. Ninkovic M., Skingle S. J., Bearcroft P. W. et al. Incidence of vertebral fractures in the first three months after orthotopic liver transplantation // Eur. J. Gastroenterol. Hepatol. - 2000. - № 12. - Р. 931-935.
24. Norris K. C., Greene T., Kopple J. et al. Baseline predictors of renal disease progression in the African American Study of Hypertension and Kidney Disease // J. Am. Soc. Nephrol. - 2006. - № 17 (10). - Р. 2928 - 2936.
25. Oliveira R. B., Cancela A. L., Graciolli F. G. et al. Early control of PTH and FGF23 in normophosphatemic CKD patients: A new target in CKD-MBD therapy? // Clin. J. Am. Soc. Nephrol. - 2010. - № 5. - Р. 286 - 291.
26. Riminucci M. et al. FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting // J. of Clinical Investigation. - 2003. - № 112. - Р. 683 - 692.
27. Saji F., Shiizaki K., Shimada S. et al. Regulation of fibroblast growth factor 23 production in bone in uremic rats. Nephron // Physiology. - 2009. - № 111 (4). - Р. 59 - 66.
28. Sitara D., Razzaque M. S., Hesse M. et al. Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophos phatemia in Phex-deficient mice // Matrix Biol. - 2004. - № 23. - Р. 421-432.
29. The ADHR Consortium. Autosomal dominant hypophosphatemic rickets is associated with mutations in FGF23 // Nature Genetics. - 2000. - № 26. - Р. 345 - 348.
30. Wesseling-Perry K., Pereira R. C., Sahney S. et al. Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism // Kidney Int. - 2011. - № 79 (1). - Р. 112-119.
31. Wolf M., Molnar M., Amaral A. et al. Elevated Fibroblast Growth Factor 23 is a Risk Factor for Kidney Transplant Loss and Mortality // J. Am. Soc. Nephrol. - 2011. - № 22. - Р. 956 - 966.
32. Yamashita T. et al. Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain // Biochemical Biophysical Research Communications. - 2000. - № 277 (2). - Р. 494 - 498.
33. Yan X., Yokote H., Jing X. et al. Fibroblast growth factor 23 reduces expression of type IIa Na + /Pi co-transporter by signaling through a receptor functionally distinct from the known FGFRs in opossum kidney cells // Genes to Cells. - 2005. - № 10 (5). - Р. 489 - 502.
Рецензия
Для цитирования:
Есаян А.М., Нимгирова А.Н., Каюков И.Г., Яковенко А.А. РОЛЬ ФАКТОРА РОСТА ФИБРОБЛАСТОВ 23-го ТИПА В РАЗВИТИИ КАРДИОВАСКУЛЯРНЫХ ОСЛОЖНЕНИЙ И НАРУШЕНИЙ КАЛЬЦИЙ-ФОСФОРНОГО ОБМЕНА У ПАЦИЕНТОВ С ХРОНИЧЕСКОЙ БОЛЕЗНЬЮ ПОЧЕК. Учёные записки Первого Санкт-Петербургского государственного медицинского университета имени академика И. П. Павлова. 2015;22(1):38-42. https://doi.org/10.24884/1607-4181-2015-22-1-38-42
For citation:
Yesayan A.M., Nimgirova A.N., Kayukov I.G., Yakovenko A.A. Role of the fibroblast growth factor type 23 in progression of complications and imbalance of calcium-phosphoric metabolism with patients suffering chronic kidney disease. The Scientific Notes of the Pavlov University. 2015;22(1):38-42. (In Russ.) https://doi.org/10.24884/1607-4181-2015-22-1-38-42